Literature DB >> 28413025

Biochemical and Biological Attributes of Matrix Metalloproteinases.

Ning Cui1, Min Hu1, Raouf A Khalil2.   

Abstract

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that are involved in the degradation of various proteins in the extracellular matrix (ECM). Typically, MMPs have a propeptide sequence, a catalytic metalloproteinase domain with catalytic zinc, a hinge region or linker peptide, and a hemopexin domain. MMPs are commonly classified on the basis of their substrates and the organization of their structural domains into collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-MMPs, and other MMPs. MMPs are secreted by many cells including fibroblasts, vascular smooth muscle (VSM), and leukocytes. MMPs are regulated at the level of mRNA expression and by activation of their latent zymogen form. MMPs are often secreted as inactive pro-MMP form which is cleaved to the active form by various proteinases including other MMPs. MMPs cause degradation of ECM proteins such as collagen and elastin, but could influence endothelial cell function as well as VSM cell migration, proliferation, Ca2+ signaling, and contraction. MMPs play a role in tissue remodeling during various physiological processes such as angiogenesis, embryogenesis, morphogenesis, and wound repair, as well as in pathological conditions such as myocardial infarction, fibrotic disorders, osteoarthritis, and cancer. Increases in specific MMPs could play a role in arterial remodeling, aneurysm formation, venous dilation, and lower extremity venous disorders. MMPs also play a major role in leukocyte infiltration and tissue inflammation. MMPs have been detected in cancer, and elevated MMP levels have been associated with tumor progression and invasiveness. MMPs can be regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs), and the MMP/TIMP ratio often determines the extent of ECM protein degradation and tissue remodeling. MMPs have been proposed as biomarkers for numerous pathological conditions and are being examined as potential therapeutic targets in various cardiovascular and musculoskeletal disorders as well as cancer.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell signaling; Collagen; Extracellular matrix; Protein degradation; Proteinases; Remodeling

Mesh:

Substances:

Year:  2017        PMID: 28413025      PMCID: PMC5430303          DOI: 10.1016/bs.pmbts.2017.02.005

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  217 in total

1.  Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases.

Authors:  W R English; B Holtz; G Vogt; V Knäuper; G Murphy
Journal:  J Biol Chem       Date:  2001-09-12       Impact factor: 5.157

2.  Collagenolytic activity in amphibian tissues: a tissue culture assay.

Authors:  J GROSS; C M LAPIERE
Journal:  Proc Natl Acad Sci U S A       Date:  1962-06-15       Impact factor: 11.205

3.  Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.

Authors:  G Velasco; S Cal; A Merlos-Suárez; A A Ferrando; S Alvarez; A Nakano; J Arribas; C López-Otín
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

Review 4.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

5.  Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins.

Authors:  O H Ryu; A G Fincham; C C Hu; C Zhang; Q Qian; J D Bartlett; J P Simmer
Journal:  J Dent Res       Date:  1999-03       Impact factor: 6.116

6.  Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction.

Authors:  David K W Chew; Michael S Conte; Raouf A Khalil
Journal:  J Vasc Surg       Date:  2004-11       Impact factor: 4.268

7.  CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase.

Authors:  Naoko Suenaga; Hidetoshi Mori; Yoshifumi Itoh; Motoharu Seiki
Journal:  Oncogene       Date:  2005-01-27       Impact factor: 9.867

8.  Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro.

Authors:  Jennifer A Kwan; Costas J Schulze; Wenjie Wang; Hernando Leon; Meltem Sariahmetoglu; Miranda Sung; Jolanta Sawicka; David E Sims; Grzegorz Sawicki; Richard Schulz
Journal:  FASEB J       Date:  2004-02-06       Impact factor: 5.191

9.  Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.

Authors:  G I Murray; M E Duncan; P O'Neil; J A McKay; W T Melvin; J E Fothergill
Journal:  J Pathol       Date:  1998-07       Impact factor: 7.996

10.  A low ratio of n-6/n-3 polyunsaturated fatty acids suppresses matrix metalloproteinase 13 expression and reduces adjuvant-induced arthritis in rats.

Authors:  Haomiao Yu; Yadong Li; Lifeng Ma; Hai Meng; Xiaodong Bai; Zihan Fan; Fei Yu; Ai Guo
Journal:  Nutr Res       Date:  2015-12       Impact factor: 3.315

View more
  219 in total

1.  Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold.

Authors:  Roman David Bülow; Peter Boor
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 2.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

3.  IL-17 signaling pathway plays a key role in laryngeal squamous cell carcinoma with ethnic specificity.

Authors:  Li Qi; Wenzhao Bao; Wei Li; Xiaoxu Ding; Aihui Yan
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Dynamic expression of MMP28 during cranial morphogenesis.

Authors:  Nadege Gouignard; Eric Theveneau; Jean-Pierre Saint-Jeannet
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-08-24       Impact factor: 6.237

5.  Adaptive reduction of human myometrium contractile activity in response to prolonged uterine stretch during term and twin pregnancy. Role of TREK-1 channel.

Authors:  Zongzhi Yin; Wenzhu He; Yun Li; Dan Li; Hongyan Li; Yuanyuan Yang; Zhaolian Wei; Bing Shen; Xi Wang; Yunxia Cao; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-03-22       Impact factor: 5.858

Review 6.  Epithelial origin of eosinophilic esophagitis.

Authors:  Mark Rochman; Nurit P Azouz; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2018-07       Impact factor: 10.793

Review 7.  Inhibition of MMPs and ADAM/ADAMTS.

Authors:  Charles J Malemud
Journal:  Biochem Pharmacol       Date:  2019-02-28       Impact factor: 5.858

Review 8.  A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.

Authors:  Sheng Zhong; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-03-21       Impact factor: 5.858

Review 9.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

10.  MiR-411 suppressed vein wall fibrosis by downregulating MMP-2 via targeting HIF-1α.

Authors:  Peng Ai; Bangli Shen; Hao Pan; Kui Chen; Jihang Zheng; Fengjun Liu
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.